https://www.selleckchem.com/pr....oducts/valemetostat-
hould be considered when designing future studies using checkpoint inhibitors in these diseases. NCT03075553. NCT03075553.Incorporating the patient voice into drug development and regulatory review process allows for the science of drug development to be more patient-centered. Dermatology is one therapeutic area where patients have the potential to provide valuable perspectives on symptoms, functional impacts, and aesthetic outcomes. Patient-reported and observer-reported outcomes play an important role in capturing concern
Like
Comment
Share
